索塔西普在肺动脉高压治疗中的应用
本文以病例讨论形式,围绕肺动脉高压(PAH)诊疗中诊断检查、一线药物选择、治疗升级、索塔西普的使用时机、安全性、实践操作及未来应用等常见临床决策进行阐述。索塔西普为激活素信号抑制剂,已基于两项关键临床试验获美国FDA批准用于PAH治疗。
要点
- 索塔西普为激活素信号抑制剂,已获FDA批准用于PAH治疗。
- 批准依据为两项关键临床试验,但试验数据不针对个体患者。
- 本文以病例为基础讨论索塔西普的时机、安全性及实践管理。
核心结论
- 索塔西普已基于两项关键临床试验获FDA批准用于PAH治疗,但现有证据尚不能完全指导个体化决策。
研究设计与样本
- 本文为「How I Do It」类型的病例讨论,非原始研究,未报告样本量。
主要发现
- PAH是肺微血管罕见病,导致毛细血管前肺动脉高压升高。
- 肺血管重塑由肺平滑肌与内皮细胞间信号异常驱动,涉及细胞增殖异常和免疫失调。
- 索塔西普为激活素信号抑制剂,基于两项关键临床试验获FDA批准用于PAH。
临床怎么用
- 文中以病例讨论形式涵盖诊断检查、一线药物选择、治疗升级及索塔西普的潜在时机。
- 临床需关注索塔西普的安全性意识、实践使用及潜在管理变化。
- 未来可能拓展用于其他肺动脉高压人群。
局限性
- 临床试验证据未针对个体患者定制,推荐常不明确或过于笼统。
- 现有知识仍存在缺口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pulmonary arterial hypertension (PAH) is a rare disease of the pulmonary microvasculature leading to elevated precapillary pulmonary hypertension. Pulmonary vascular remodeling, a characteristic of PAH, is driven by dysfunctions in the signaling between the pulmonary smooth muscle and endothelial cells with abnormalities that affect cell proliferation and immune dysregulation. Sotatercept, an activin signaling inhibitor, has recently been approved by the US Food and Drug Administration for the treatment of PAH based on two pivotal clinical trials. Evidence-based clinical trials have provided a framework to guide clinicians treating the disease; however, they are not tailored to the individual patient. Often, recommendations from these data are unclear or too general, due to remaining gaps in knowledge. In this edition of "How I Do It," we provide a case-based discussion of common clinical decisions regarding diagnostic testing, choice of first-line agents, escalation of therapy, potential timing of sotatercept, safety awareness, practical use, potential management changes, and the future use of sotatercept in other pulmonary hypertension cohorts.
引用
- Preston IR, Lewis D, Gomberg-Maitland M, et al. Using Sotatercept in the Care of Patients With Pulmonary Arterial Hypertension. Chest. 2024. PMID: 39004216. doi:10.1016/j.chest.2024.06.3801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。